Neurobiological rhythms in critical care: A commentary on intensive care unit music therapy efficacy and mechanism

Abstract

This is a commentary on the randomized controlled trial by Mukhtar et al, which reported findings from a single, 30-minute music therapy session administered prior to extubation in mechanically ventilated intensive care unit (ICU) patients. The study found significant acute improvements in psychological distress and physiological stability, alongside an extraordinary, unexpected reduction in ICU length of stay and ICU mortality. These dramatic hard outcomes suggest a mechanism beyond distraction, requiring sustained modulation of the prefrontal cortex-limbic circuit and the substantial upregulation of neuroplasticity markers, specifically brain-derived neurotrophic factor (BDNF). Critically, the molecular changes required for structural reorganization and clinical benefits like reduced mortality necessitate repeated, sustained stimulus, a condition that sharply contrasts with the study's brief protocol. This presents a major mechanistic conundrum. Future research must therefore employ multisession, placebo-controlled, multicenter trials designed to measure objective, sustained neurobiological changes (e.g., serum BDNF, heart rate variability) to definitively link music therapy to reduced morbidity and mortality in critical care.

Key Words: Music therapy; Neuroplasticity; Intensive care unit; Critical care; Brain-derived neurotrophic factor; Anxiety

Core Tip: The single 30-minute music therapy session achieved remarkable results, including reduced patient anxiety, pain, and, crucially, lower intensive care unit (ICU) mortality (7.4% vs 19.1%) and a shorter ICU length of stay (4.97 days vs 5.70 days). To justify these powerful, long-term findings, the intervention must engage fundamental neurobiological pathways. Since structural brain changes and the upregulation of factors like brain-derived neurotrophic factor require sustained effort, the study's brief, one-time protocol and unblinded design introduce a major mechanistic conundrum. Future, rigorous trials with repeated sessions and credible sham controls are essential to prove that music's neurobiological power, and not just a strong attention effect, drives recovery in critically ill patients.

TO THE EDITOR

Music therapy in critical care is a low-risk, patient-centered intervention used to reduce stress, anxiety, and pain, enhancing overall well-being. Recognized as a supportive care option by organizations like the Society of Critical Care Medicine[1], its biological plausibility lies in its ability to modulate the autonomic nervous system.

The paper by Mukhtar et al[2] reports a randomized controlled trial where a single 30-minute session was administered to mechanically ventilated patients before extubation. The study demonstrated significant improvements in physiological stability and reported an extraordinary reduction in intensive care unit (ICU) length of stay (LOS) and mortality. While these results suggest music is a potent intervention, the magnitude of the “hard” outcomes from a brief, single session creates a significant challenge in interpretation. This commentary evaluates these findings, arguing that while acute symptom relief is biologically plausible, the claimed impact on mortality likely reflects methodological confounding or chance rather than a direct neurobiological mechanism.

Acute efficacy: Validation of psychological and physiological outcomes

The findings regarding acute symptom management align well with established literature.

Symptom reduction and stabilization: Consistent with prior reviews[3,4], the intervention group showed significant post-intervention reductions in anxiety, dyspnea, and pain. These shifts reflect a reduction in sympathetic nervous system activation[5,6]. This acute stabilization is a high-value clinical goal that facilitates successful extubation, regardless of whether it alters long-term survival.

The paradox of hard outcome benefits: The reported reduction in ICU LOS (4.97 days vs 5.70 days) and mortality (7.4% vs 19.1%) is methodologically startling[2]. While music interventions are valuable, a single 30-minute dose is conventionally insufficient to produce the structural or functional biological changes required to alter major clinical trajectories. These findings must be viewed with caution; they may reflect residual confounding, such as baseline imbalances in illness severity (e.g., sequential organ failure assessment or Acute Physiology and Chronic Health Evaluation II scores) or unintended “care-process” effects. For instance, a calmed patient may appear more “ready” for extubation to unblinded staff, leading to earlier discharge and lower complication rates-a behavioral rather than purely biological pathway.

The mechanistic landscape: Plausibility vs overcommitment

To understand the disconnect between dose and outcome, we must differentiate between acute emotional regulation and sustained neuroplasticity.

The prefrontal cortex-limbic circuit: Acute control: Music modulates neural circuits responsible for emotion and stress, specifically the Prefrontal Cortex-Hippocampus-Amygdala circuit[7]. A single session can feasibly induce top-down control, dampening the amygdala and reducing the HPA-axis stress response. This explains the acute physiological “calm” observed by Mukhtar et al[2].

Candidate mechanisms for sustained change: Brain-derived neurotrophic factor and beyond: For music to drive structural recovery, it must theoretically induce sustained neuroplasticity, often linked to brain-derived neurotrophic factor (BDNF)[8,9]. However, several caveats apply: (1) Dose-dependency: BDNF upregulation typically requires repeated, sustained stimuli. It is biologically improbable that a single dose could induce the protein expression necessary to reduce mortality by 11%; (2) Translational gap: Much of the FNDC5/BDNF evidence stems from preclinical animal models[9]. In the human ICU, the profound neuroendocrine disruption and systemic inflammation of critical illness may blunt or alter these plasticity pathways, making animal-to-human extrapolation difficult; and (3) Alternative pathways: BDNF is only one candidate. Other mechanisms-such as vagal-mediated anti-inflammatory effects, improved sleep architecture, or reduced requirements for sedative drugs (which are themselves neurotoxic)-likely contribute to the overall therapeutic effect.

Methodological conundrums

The contrast between the single dose and the profound hard outcomes reveals significant limitations in the current evidence base.

Intervention clarity: The study describes a single listening session. It is important to distinguish “music listening” from “music therapy”, the latter of which involves a credentialed therapist and individualized goals. Conflating the two risks overstating the intervention's complexity.

The unblinded bias and attention effect: Without a “neutral sound” placebo, benefits may be driven by a non-specific Hawthorne effect[10]. Furthermore, music may simply act as a marker for higher-quality, attentive nursing care rather than being the active agent of mortality reduction.

Publication and confirmation bias: The unusually large effect sizes in a single-center study raise the risk of chance findings amplified by small sample size. Future trials must employ preregistration and independent replication to protect the field from premature claims.

Future directions: A falsifiable research agenda

The field must transition to trials that align protocols with neurobiological requirements. We propose the following falsifiable hypotheses: (1) Dose-response: If music therapy reduces mortality via neuroplasticity, then repeated daily sessions will show a stronger correlation with clinical outcomes than single sessions; (2) Biomarker mediation: Changes in heart rate variability and serum BDNF will statistically mediate the relationship between music exposure and ICU LOS; and (3) Standardization: Standardized music (specific tempo/frequency) will produce more consistent autonomic shifts than attendant-chosen music.

CONCLUSION

This commentary does not argue against the use of music in the ICU; on the contrary, it remains a low-risk, high-value tool for patient-centered symptom relief. However, we must guard against the overinterpretation of hard outcomes derived from biologically insufficient dosing. By demanding more rigorous, multicenter trials and mechanistic clarity, we ensure that music therapy is integrated into critical care based on evidence rather than over-extrapolated anomalies.